Background
Understanding patterns of oral HIV PrEP use after initiation in pregnancy could guide adherence support throughout the perinatal period.
Methods
We analyzed data from a randomized trial conducted in Western Kenya between February 2022 and September 2024 (NCT04472884). The trial enrolled pregnant women initiating daily oral HIV PrEP in routine antenatal clinics and followed them until 9 months postpartum. We evaluated PrEP use trajectories and applied Cox models to estimate time to PrEP discontinuation. Poisson regression, adjusted for study site, with robust SEs was used to estimate discontinuation after stillbirth or neonatal loss.
Results
Overall, 600 pregnant women initiated HIV PrEP and 312 (52%) discontinued PrEP at least once before 9-months postpartum; median time to first discontinuation was 5.8 months (IQR: 2.2-10.7). Women frequently discontinued HIV PrEP in pregnancy (16%) and at 6-months postpartum (20%, Figure 1A); 39 (12.5%) women who discontinued subsequently restarted PrEP. Compared to women who started antenatal care (ANC) in their first trimester, women were more likely to discontinue HIV PrEP if they started ANC in their second trimester (HR: 1.61, 95% CI: 1.14-2.28, p=0.007) or third trimester (HR: 1.85, 95% CI: 1.22-2.81, p=0.004, Figure 1B). Primigravida women were 40% more likely to discontinue PrEP compared to multigravida women (HR: 1.40, 95% CI: 1.09-1.80, p=0.008). Women who experienced side effects on oral PrEP were 66% more likely to discontinue (HR: 1.66, 95% CI: 1.19-2.31, p=0.003). High pill-taking self-efficacy was associated with a 72% lower risk of discontinuation (HR: 0.28, 95% CI: 0.20-0.39, p<0.001). Compared to women with no self-perceived HIV risk, women with moderate risk (HR: 0.45, 95% CI: 0.27-0.75, p=0.002) and great risk (HR: 0.08, 95% CI: 0.02-0.29, p<0.001) were less likely to discontinue oral PrEP. Women who experienced stillbirth or neonatal loss were over twice as likely to discontinue PrEP compared to women without loss (RR: 2.56, 95% CI: 1.35-4.85, p=0.03).
Conclusions
Interventions that enhance self-efficacy and refine risk perception could help promote PrEP persistence for pregnant women who initiate PrEP. Strengthening integrated maternal and HIV PrEP support, especially for women who are primigravida, have side HIV PrEP effects, or experience perinatal loss, could also address PrEP persistence challenges.
Table or Figure
